Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer by Dickinson, L et al.
 1 
PSA versus MR imaging parameters for assessing oncological outcomes following 
HIFU focal therapy for localised prostate cancer 
Louise Dickinson1, 2, Hashim U. Ahmed1, 2, Richard G. Hindley3, Neil McCartan1, Alex 
Freeman4, Clare Allen5, Mark Emberton1, 2, Alex P. Kirkham5 
 
1. Division of Surgery and Interventional Sciences, University College London, UK 
2. Department of Urology, University College London Hospitals NHS Foundation 
Trust, UK 
3. Department of Urology, Basingstoke Hospital, Hampshire Hospitals NHS 
Foundation Trust, UK 
4. Department of Histopathology, University College London Hospitals NHS 
Foundation Trust, UK 
5. Department of Radiology, University College London Hospitals NHS Foundation 
Trust, UK 
 
Corresponding Author 
Dr Louise Dickinson MBBS MRCS PhD, Specialist Registrar in Radiology 
Present address: Department of Radiology, Northwick Park Hospital, London North 
West Hospitals NHS Trust, Watford Road, Middlesex, HA1 3UJ 
E-mail: ldickinson@doctors.org.uk 
Tel:  0044 208 8693890 
Fax: 0044 208 8693907 
 
Funding: Medical Research Council (UK), Pelican Cancer Foundation charity, St Peters 
Trust charity, Prostate Cancer UK 
 
 
 
 
 
 2 
Abstract  
Introduction 
Focal therapy for localised prostate cancer has the potential for oncological control 
without the side effects of radical therapies. However, there is currently no validated 
method for monitoring treatment success. We assessed the diagnostic performance 
of PSA parameters and MRI compared to histological outcomes following focal 
therapy. 
 
Patients and Methods 
Patients from three Ethics Review Board approved prospective studies of focal HIFU 
(Sonablate 500™) for localised prostate cancer (T1c-T3a, Gleason grade ≤4+3, PSA 
≤20). Post-HIFU prostate specific antigen (PSA) nadir, 6-month PSA, PSA density, and 
early (<3 week) and late (6-month) MRI (T2 weighted, dynamic contrast enhanced 
+/- diffusion-weighted) was assessed for predictive accuracy of cancer on post-
operative biopsy, using Receiver Operating Characteristic (ROC) analysis and 
sensitivity, specificity and positive (PPV) and negative (NPV) predictive estimates. 
ROC areas for MRI and PSA were compared. Calculations for statistical significance 
(p-value ≤0.05) were obtained in a subset of patients comparing area under ROC for 
6-month MRI and PSA criteria, across 4 different histological definitions of disease 
significance.  
 
Results 
111/118 men underwent at least one post-operative biopsy (median 6 cores), with 
an overall positive biopsy rate of 37% (41/118), over a mean follow-up period of 716 
 3 
days post-HIFU. Area under ROC for early and late MRI were (depending on 
definition of significant disease) 0.65–0.76, and 0.77–0.85, respectively, with 
sensitivity, specificity and negative predictive values of 68-91%, 52-55% and 85-98% 
(early MRI) and 63-80%, 67-73% and 86-97% (late MRI). The area under the ROC 
curve was statistically significantly higher for late MRI than 6 month and nadir PSA 
for residual disease >3mm or any Gleason 4 tumour.  
 
Conclusions 
Early and later MRI performed better than PSA measurements in the detection of 
residual tumour after focal therapy.  
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1. Introduction 
Focal therapy is an emerging treatment for localised prostate cancer, using a range 
of technologies (1-6). Early reports of HIFU and cryotherapy have demonstrated low 
rates of genitourinary side-effects, in conjunction with acceptable short-term cancer 
control (7). However, one of the principal concerns in focal therapy is the lack of a 
validated, non-invasive test for monitoring oncological outcome (8). Whilst PSA 
parameters are an established means of monitoring biochemical outcomes after 
radical treatment, their value after focal treatment is less certain, because of the 
variable contribution of residual prostate.  
 
Biopsy is invasive, with an associated risk of significant morbidity (9) and we know 
that systematic biopsies for small foci of tumour are subject to considerable under-
sampling and under-grading compared to targeted samples (10). Conversely, imaging 
has the capability of visually monitoring the whole prostate (treated and untreated 
areas) and of providing information on changes in characteristics that might signal 
residual disease, progression of untreated secondary lesions, or development of de 
novo lesions. MRI has also shown good performance for the detection of residual 
tumour after whole prostate HIFU ablation, with sensitivities for detection residual 
disease of 73-87% (11). 
 
We aimed to assess the diagnostic performance of PSA parameters and mpMRI for 
the detection of residual disease found at biopsy after focal HIFU, using four 
histological threshold definitions of significant disease.  
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2. Patients and Methods 
2.1 Patients 
Three early development studies evaluating focal HIFU treatment (Sonablate 500®) 
for localised prostate cancer have now been completed at our institutions. Research 
committee approval and written, individual patient consent was obtained for each 
study. In the first study (n=20) (1), treatment was delivered as a hemi-ablation to 
unilateral disease; in the second study (n=42) (2), treatment involved more targeted 
‘focal’ ablation of cancer lesion(s), and in the third (n=56), ‘index lesion’ ablation was 
performed to the dominant clinically significant lesion(s) only (3). The HIFU 
treatments occurred between 2006 and February 2011, and all men entered a 
prospective HIFU registry on completion of the study period, for collection of on-
going oncological (including PSA, mpMRI, biopsy) and quality of life data. All of the 
118 patients in these trials were included. 
 
Short-term (12-month) adverse event, genitourinary functional, biochemical and 
histological outcomes have been published on the results on all three studies (1-3).  
The purpose of this current report was to assess the accuracy of MRI and PSA 
outcomes against histopathology on all participants within the three studies who 
underwent at least one post-HIFU biopsy. Additionally, this analysis includes registry 
data extending beyond the 12-month outcomes previously published (1-3). 
 
2.2 MRI 
All pre- and post-HIFU MRI was performed using either a 1.5 Tesla or 3 Tesla MRI 
scanner and a pelvic phased array receiver, pelvic coil, full protocol of T1 and T2 
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weighted turbo-spin echo images and dynamic post gadolinium volume acquisition. 
Diffusion-weighted images were also obtained in all patients pre-HIFU and in 15 
patients post-HIFU (6-month scan) (appendix table A).  
 
The early MRI was performed between 48 hours and 3 weeks post-HIFU, as a 
preliminary assessment of treatment quality, with coverage of the tumour scored 
between 1 and 3 (1 indicating the lowest suspicion of residual tumour). If the margin 
of the non-enhancing prostate was close to the treated tumour we scored 2, and 3 if 
there was enhancement in the tumour location.  
 
The late MRI was performed at approximately 6-months, pre- follow-up biopsy. This 
was the earliest stage that evidence of any residual tumour was expected to become 
apparent. Prior to this time, resolving necrotic tissue has been found to mask 
residual cancer (12). Early and late MRI were reported and graded prospectively by 
one of a group of specialist uroradiologists with at least 3 years of prostate MRI 
experience. A 5-point Likert-type scale for likelihood of residual tumour was used, 
with a score of 3 or higher considered positive (as per standard departmental 
practice, prior to the introduction of the PI-RADS scoring system™). In a few cases 
where no score had been assigned prospectively, the images were reviewed and 
graded retrospectively by a single experienced uroradiologist (AK), without 
knowledge of the post-treatment histological outcome.  
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Figure 1. MRI images before (a and b), early post (c), and 6 months post focal HIFU to 
a Gleason 3+4 right anterior lesion. The lesion is shown on T2 (a) and dynamically 
enhanced (b) images (arrow in each) before treatment. Early post HIFU (c) the 
treatment margin is close to the location of the tumour (arrow) and the score was 
equivocal for residual tumour (score 2). Late post HIFU (d) a rim of enhancement at 
the site of the tumour was scored as positive on MRI (score 5) and the biopsy was 
positive for all definitions of significance.  
 
 
a b
c d
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2.3 PSA 
Serum PSA levels were obtained pre-HIFU, and at 6 weeks, 3, 6, 9, 12 months, and 
approximately 6-monthly thereafter. PSA nadir was calculated as the lowest PSA 
achieved at any point following focal-HIFU. Post-operative PSA density was 
calculated as 6-month PSA level divided by the volume of residual tissue, as assessed 
by the 6-month post-HIFU MRI. 
 
2.4 Biopsies 
A limited number of representative biopsies were taken at 6-months from the 
treated area of the prostate, at an approximate density of 1 per millilitre of residual 
tissue as assessed on ultrasound.  If the late MRI indicated any areas of suspicion, 
these were also targeted at biopsy (cognitive targeting). This protocol was 
standardised across all of the focal therapy studies included in this analysis. 
Additional, ‘for-cause’ biopsies were performed in some men with on-going 
suspicion of residual tumour in later follow-up (either a suspicious MRI or continuing 
rise in PSA). Only biopsies in the area of the treatment were included in our analysis.  
 
2.5 Disease stratification 
In order to differentiate between different burdens of residual tumour, and to assess 
thresholds for detection by imaging and biochemical parameters, we divided post-
HIFU tumour into the following categories: 
 
1. Any cancer 
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2. Gleason pattern 4 or 5 and/or >3mm maximum cancer core length (UCL 
definition 2) (13). 
3. >3mm maximum cancer core length (any disease grade) 
4. Gleason pattern 4 or 5 (any cancer core length) 
 
2.6 Statistical analysis 
PSA nadir, 6-month post-operative PSA, post-operative PSA density, early and late 
MRI outcomes were assessed for predictive accuracy of histological residual tumour 
on post-operative biopsy using area under the Receiver Operating Characteristic 
(AUROC) analysis. All figures given are for fitted curves produced with the online 
ROC calculator ROCfit, which generates the maximum likelihood fit of a binormal 
model (14). We performed two analyses: firstly using only the 6-month biopsy data, 
and secondly including the result of any positive biopsy. Areas under the ROC curve 
for MRI and the PSA criteria were compared using the method described by Hanley  
(15).  
 
Additionally, estimates of sensitivity, specificity and positive (PPV) and negative 
(NPV) predictive values were calculated after dichotomising the MRI results so that 
equivocal scans were considered positive (2 or 3 considered positive on the early 
scan, and 3-5 considered positive at 6 months)  
 
3. Results 
Of 118 men with localised prostate cancer (T1c-T3a, Gleason grade ≤4+3, PSA ≤20) 
who underwent focal ablation within any of the three prospective 12-month studies, 
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111 received at least one post-operative biopsy (at a median of 190 days post-HIFU, 
with a median of 6 cores). Sixteen of these men received a second ‘for cause’ biopsy 
(a mean 716 days post-HIFU), due to suspected residual or recurrent tumour (usually 
a suspicious MRI or a rise in PSA). Baseline characteristics are detailed in appendix 
table B.  
 
109 of the 111 men with a 6-month biopsy also had a 6-month MRI and full PSA 
data. This group was used to analyse both the performance of 6-month MRI and PSA 
measurements. The performance of early MRI was assessed using a smaller group of 
105 men who underwent a scan at <1 month and biopsy at 6 months.  
 
3.1 Biopsy Outcomes 
Twenty-eight men (25%) had residual disease on first biopsy, of whom 12/28 (43%) 
fulfilled our criteria 2, 3, or 4 for clinically significant disease. After for-cause biopsy, 
a total of 41 men (37%) had received a positive biopsy post-treatment, of whom 
21/41 (51%) fulfilled criteria 2, 3 or 4 for clinical disease significance. The median 
cancer core length of residual disease on any biopsy was 2mm (range 1–10mm). 
  
 Any disease >3mm CCL or 
any Gleason 4 
>3mm CCL Any Gleason 
pattern 4 
After initial 
biopsy 
28 (25%) 12 (11%) 10 (9%) 7 (6%) 
After any 
biopsy 
41 (37%) 21 (19%) 14 (13%) 14 (13%) 
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Table 1. Disease detection on initial and subsequent biopsy according to different 
levels of disease burden 
 
3.2 PSA Parameters 
The median pre HIFU PSA was 7ng/ml, and median post treatment nadir, 6-month, 
and PSA density values were 1.6, 2.0 and 4.5ng/ml respectively. Six-month and nadir 
PSA levels demonstrated similar AUROC accuracies for residual disease detection 
against initial biopsy (0.63 - 0.71). For both groups, additional information on 
subsequent biopsy resulted in globally reduced accuracy rates. The results for PSA 
density were similar, but with a higher accuracy (0.78) for the detection of Gleason 4 
or 5 disease.  
 
 
INITIAL BIOPSY (standard errors in brackets) 
 
 Any disease >3mm CCL or 
any Gleason 4 
>3mm CCL Any Gleason 
pattern 4 
PSA nadir  0.63 (0.055)  0.64 (0.072)  0.71 (0.066)  0.66 (0.096)  
6 month PSA 0.64 (0.052)  0.65 (0.068)  0.71 (0.058)  0.67 (0.092)  
PSA density 0.64 (0.070) 0.66 (0.070)  0.67 (0.077)  0.78 (0.064)  
 
ANY BIOPSY (standard errors in brackets) 
 
 Any disease >3mm CCL or 
any Gleason 4 
>3mm CCL Any Gleason 
pattern 4 
PSA Nadir 0.58 (0.053)  0.56 (0.064)  0.67 (0.070)  0.54 (0.077)  
6 month PSA 0.58 (0.053)  0.56 (0.065)  0.67 (0.066)  0.50 (0.081)  
PSA density 0.62 (0.054)  0.59 (0.073)  0.67 (0.082)  0.59 (0.093)  
 
Table 2. ROC characteristics of PSA parameters against initial and subsequent biopsy.  
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The p values for the comparison of the PSA parameters AUC with that for 6 month 
MRI (Table 4) are given in appendix table C.  
 
3.3 MRI  
3.3.1 Early MRI  
105 men received an early MRI (at a median of 15 days after biopsy, range 7-29) of 
which 54 (51%) were considered equivocal or positive. Moderate accuracy rates 
were achieved for predicting the presence of residual cancer, with AUROC ranging 
between 0.65 and 0.76. Negative predictive value for residual tumour was high (85% 
for any tumour, but 98% for the three definitions of significant disease), but positive 
predictive values were low across all disease categories (ranging 9.4%–32.1%). 
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INITIAL BIOPSY 
 
 Any disease >3mm CCL or 
any Gleason 4 
>3mm CCL Any Gleason 
pattern 4 
Sensitivity (%) 17/25 (68%) 10/11 (91%) 9/10 (90%) 5/6 (83%) 
Specificity (%) 44/80 (55%) 51/94 (54%) 51/95 (54%) 51/99 (52%) 
PPV (%) 17/53 (32%) 10/53 (19%) 9/53 (17%) 5/53 (10%) 
NPV (%) 44/52 (85%) 51/52 (98%) 51/52 (98%) 51/52 (98%) 
ROC (standard 
error) 
0.65 (0.070) 0.76 (0.063) 0.76 (0.067) 0.75 (0.11) 
 
ANY BIOPSY 
 
 Any disease >3mm CCL or 
any Gleason 4 
>3mm CCL Any Gleason 
pattern 4 
Sensitivity (%) 25/37 (68%) 15/19 (79%) 12/14 (86%) 8/12 (67%) 
Specificity (%) 40/68 (59%) 48/86 (56%) 50/91 (55%) 48/93 (52%) 
PPV (%) 25/53 (47%) 15/53 (28%) 12/53 (23%) 8/53 (15%) 
NPV (%) 40/52 (77%) 48/52 (92%) 50/52 (96%) 48/52 (92%) 
ROC (standard 
error) 
0.69 (0.064) 0.72 (0.063) 0.75 (0.064) 0.64 (0.10) 
 
Table 3. Accuracy rates of early MRI against initial and subsequent biopsy 
 
When early MRI outputs were correlated with the outcomes of any positive biopsy, 
including repeat biopsy in those 16 men receiving one, sensitivity and negative 
predictive values decreased marginally for the detection of clinically significant 
tumour. However, specificity rates remained similar, and positive predictive values 
improved.  
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3.3.2 Later MRI (6 month Follow-up) 
38 of 109 men (35%) were considered equivocal or positive on MRI at a median of 6 
months (range 154-280 days).  Against initial biopsy, late MRI demonstrated greater 
accuracy for predicting residual tumour than early MRI, with AUROC ranging 
between 0.77 and 0.85 (highest for disease >3mm). As with the early MRI, the late 
MRI demonstrated high negative predictive values for ruling-out the presence of 
clinically significant tumour (86-97%) but low positive predictive values (14-44%). 
Specificity rates were similar across all disease categories.  
 
Again, the additional information from subsequent positive biopsy contributed only 
marginally, with the greatest change observed in the positive predictive values of 
late MRI for ruling-in residual cancer. 
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INITIAL BIOPSY 
 
 Any disease >3mm CCL or 
any Gleason 4 
>3mm CCL Any Gleason 
pattern 4 
Sensitivity (%) 17/27 (63%) 9/12 (75%) 8/10 (80%) 5/7 (71%) 
Specificity (%) 60/82 (73%) 67/97 (69%) 68/99 (69%) 68/102 (67%) 
PPV (%) 17/39 (44%) 9/39 (23%) 8/39 (21%) 5/39 (13%) 
NPV (%) 60/70 (86%) 67/70 (96%) 68/70 (97%) 68/70 (97%) 
ROC (standard 
error) 
0.77 (0.054) 0.83 (0.056) 0.85 (0.053) 0.79 (0.081) 
 
ANY BIOPSY 
 
 Any disease >3mm CCL or 
any Gleason 4 
>3mm CCL Any Gleason 
pattern 4 
Sensitivity (%) 24/40 (60%) 14/21 (67%) 11/14 (79%) 9/14 (64%) 
Specificity (%) 54/69 (78%) 63/88 (72%) 67/95 (71%) 65/95 (68%) 
PPV (%) 24/39 (62%) 14/39 (36%) 11/39 (28%) 9/39 (23%) 
NPV (%) 54/70 (77%) 63/70 (90%) 67/70 (96%) 65/70 (93%) 
ROC (standard 
error) 
0.76 (0.068) 0.78 (0.067) 0.85 (0.056) 0.72 (0.087) 
 
Table 4. Accuracy rates of late MRI against initial and subsequent biopsy 
 
A summary of the post-operative PSA and MRI outcomes are detailed in appendix 
table D. 
 
3.4 Statistical comparisons 
To avoid effects due to large numbers of comparisons, we restricted the statistical 
tests to comparing 6-month MRI with PSA criteria in a single defined group of 109 
 16 
patients. In all 24 comparisons (p values given in Table 2) the AUC was higher for MRI 
than for PSA criteria, and in six cases the difference was statistically significant.  
 
 
 
Figure 2. Fitted ROC curves comparing early and late MRI and all PSA parameters for 
the detection of UCL definition 2 for cancer (category 3).   
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4. Discussion 
In this short-term study, MR imaging provided a more accurate means of detecting 
residual cancer than PSA biochemical parameters, against a biopsy histopathology 
reference standard, with high AUROC of up to 0.85 by late MRI in the detection of 
different criteria for clinically significant tumour.  
 
Early and late MRI achieved very high negative predictive values, at 98% and 97%, 
respectively, for ruling-out the presence of residual clinically significant tumour on 
post-treatment biopsy. Negative predictive value in this context must be interpreted 
with caution, as the number of positive biopsies was low for some of the definitions 
of significance.  The low positive predictive values achieved are likely to reflect the 
chosen cut-off of 3 on the Likert scale as ‘positive’, and threshold effects due to small 
tumours being classified as ‘negative’ for some of the definitions of significance.  
 
Our results suggest that mpMRI is a useful test for assessing focal HIFU treatment, 
and in particular for confirming the absence of residual cancer in the short term. 
Although the negative predictive values of the early and later MRIs are similar, the 
considerably higher specificity and positive predictive value of the later (6 month) 
scan means that it is potentially more useful.  
 
The clinical implications extend beyond HIFU ablation, and are potentially applicable 
to any focal therapy. Firstly, those assessed as at high risk for under-treatment could 
be identified early on MRI, and closely monitored, or offered further treatment at 
the first appropriate opportunity. Secondly, MRI may enable a reduction in the 
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number of cores performed during a follow up biopsies by targeting positive areas, 
or a reduction in the need for post treatment biopsy if negative, although this latter 
application remains speculative.  
 
By analysing accuracy rates against several definitions of residual tumour burden, we 
were able to show that the highest accuracy levels were achieved when identifying 
lesions over 3mm. The term ‘clinically significant’ has recently been adopted within 
research papers in order to differentiate between potentially indolent tumour 
compared to higher risk disease that is likely to warrant treatment (16-19) , although 
none have yet been validated. For this study we adopted several criteria of disease 
burden, using 3mm and Gleason 4 as thresholds of clinical significance according to 
UCL criteria 2 (13), not for the purpose of establishing a definition for clinical 
significance, but rather to assess different thresholds of volume and grade that 
might be predicted by either biochemical or imaging tools. 
 
We should emphasise that the diagnostic performance of MRI in the post focal HIFU 
context appears potentially better than in the more common setting of a triage test 
to investigate men with a raised PSA:  only 10 out of our 28 positive patients had a 
cancer core length >3mm, and our sensitivity of 80% for a biopsy with a CCL >3mm 
compares well with the finding of Villers et al of a sensitivity of 77% for lesions 
>0.2cc in the pre-biopsy setting (20) (a 0.2cc lesion is equivalent to a 7mm sphere, 
and usually returns a MCCL of >3mm (13)). 
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There are many limitations to this study. Whilst the cohort had all received focal 
therapy within three 12-month prospective studies involving protocol-mandated 
serum PSA, MRI and biopsies, and subsequently prospective registry data collection, 
our analysis included some MRI data collated in a retrospective manner, albeit 
blinded to the post-operative PSA and histology results. 
 
Our analysis was performed on a heterogeneous cohort of men, with varied baseline 
disease burden, undergoing different focal therapy protocols. Of particular 
relevance, the post-operative PSA response in those men treated with ablation to 
the index lesion and with known untreated clinically insignificant disease may have 
been significantly different to those without untreated lesions. However, it could be 
argued that all the treatment protocols adopted an ‘index lesion’ approach, as the 
complete absence of low volume, insignificant disease within the untreated prostate 
cannot be fully excluded on pre-operative mpMRI and transperineal template 
mapping biopsies.  
 
All of the focal therapy studies included were initiated prior to contemporary 
consensus statements of patient eligibility and follow-up criteria (21). As men 
received the first post-operative biopsy within a relatively short follow-up period 
(averaging just over 7 months from treatment), biopsy may not have accurately 
targeted and sampled any small residual lesions, potentially introducing sampling 
bias. It was in order to capture such cases that we included subsequent biopsy 
results, although with no significant effect identified on the PSA and MRI 
performance characteristics.  
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Finally, the MRI protocol changed at our institution over the study period of 6 years. 
While the majority of patients underwent 1.5T scans involving just T2 and 
dynamically enhanced sequences, some had 3T scans and others also underwent 
diffusion-weighted scans. Both of these are likely to improve performance (with 
some data on diffusion existing in the post treatment context (22)), so that we may 
be underestimating the potential performance of modern MRI.  
 
5. Conclusions 
Whilst clinical guidance now exists on the most accurate means of localising and 
identifying disease to plan and conduct focal treatment, our understanding of how 
men receiving focal therapy are most appropriately followed up remains limited. This 
small, short-term study provides a first step to reducing that uncertainty. We have 
shown that MR imaging, in the form of early and later mpMRI, strongly predicts a 
negative biopsy after focal therapy for localised prostate cancer, whilst PSA 
parameters are less reliable.  
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Early post HIFU MRI sequence protocol 
 TR TE Flip 
angle/ 
degrees 
Plane Slice 
thickness 
(gap) 
Matrix 
size 
Field of 
view 
/mm 
Time for scan 
T2 TSE 5170 92 180 axial 
 
3mm (10% 
gap) 
256x 
256 
180 x 
180 
3m 54s each 
T1 TSE 502 15 150 axial 3mm (10% 
gap) 
256 x 
256 
200 x 
200 
2m 44s 
VIBE with fat 
sat 
5.61 2.52 15 axial 3mm (20% 
gap) 
192x 
192 
260 x 
260 
≥7m 
(sequential 16s 
acquisitions)  
T1 post 
contrast fat 
sat 
461 19 150 Axial, 
coronal 
3mm 
(10% gap) 
256 x 
256 
200 x 
200 
4m 39s each 
Late post HIFU MRI sequence protocol 
 TR TE Flip 
angle/ 
degrees 
Plane Slice 
thickness 
(gap) 
Matrix 
size 
Field of 
view 
/mm 
Time for scan 
T2 TSE 5170 92 180 axial, 
coronal 
 
3mm (10% 
gap) 
256x 
256 
180x 
180 
3m 54s (ax), 
4m18s (cor)  
VIBE with fat 
sat 
5.61 2.52 15 axial 3mm (20% 
gap) 
192x 
192 
260x 
260 
7m at least 
(sequential 16s 
acquisitions)  
Diffusion  
b values: 0, 
150, 500, 
1000* 
2200 98  axial 5mm 172x 
172 
 
260x 
260 
5m 44s 
(16 averages)  
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Appendix  
Appendix Table A. MRI pulse sequences at 1.5T.  The parameters were similar or of 
slightly higher spatial resolution for scans at 3T.  * Diffusion-weighted imaging was 
performed in 15 patients. 
 
 
Age (years), mean (SD; range) 62.9 (5.9; 48 – 77) 
Serum PSA (ng/ml), median (IQR) 6.8 (5.7 – 9.4) 
Prostate volume (ml), median (IQR) 35 (28 - 47) 
Type of tissue-sparing HIFU treatment/ trial 
Hemi-ablation 
Focal ablation 
Index lesion ablation 
 
18 (16%) 
40 (36%) 
53 (48%) 
Type of pre-treatment biopsy on which focal 
treatment was planned  
TRUS biopsy 
TPM biopsy 
 
 
21 (19%) 
90 (81%) 
Pre-treatment Gleason grade 
3+3 
3+4 
4+3 
 
31 (28%) 
71 (64%) 
9 (8%) 
Total cores (n), median (IQR) 41 (29 – 63) 
Total positive cores (n), median (IQR) 7 (4 – 11) 
Maximum cancer core length (mm), median (IQR) 5 (4 – 8) 
 
Appendix Table B. Baseline patient characteristics. 
 
Diffusion 
b=1400* 
2200 98  axial 5mm 172 x 
172 
320x 
320 
3m 39s 
(32 averages) 
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INITIAL BIOPSY 
 
 Any disease >3mm CCL or 
any Gleason 4 
>3mm CCL Any Gleason 
pattern 4 
PSA nadir   0.065  0.037 0.087  0.26 
6 month PSA  0.1  0.037 0.076  0.36 
PSA density  0.13  0.063  0.054  0.98 
 
ANY BIOPSY  
 
 Any disease >3mm CCL or 
any Gleason 4 
>3mm CCL Any Gleason 
pattern 4 
PSA Nadir  0.034  0.018  0.03  0.11 
6 month PSA  0.033  0.018  0.043  0.066 
PSA density  0.096  0.063  0.069  0.29 
 
 Appendix Table C. Table of p-values of PSA parameter ROC against 6-month MRI 
ROC 
 
 
Post-treatment nadir PSA (ng/ml), median (IQR) 1.6 (0.8 – 2.8) 
Post-treatment 6-month PSA (ng/ml), median (IQR) 2.0 (1.0 - 3.4)  
Post-treatment PSA density (ng/ml), median (IQR) 4.5 (3.4 – 6.4) 
Equivocal or positive early MRI (score 2 or 3) (number, %) 54/ 105 (51%) 
Equivocal or positive late MRI (score 3, 4 or 5) (number, %) 38/109 (35%) 
 
 
Appendix Table D. Post-operative PSA and MRI outcomes 
 
